Tychon Biosciences

Tychon Biosciences is a biotechnology company founded in 2015, specializing in the Immuno-oncology marketplace. The company's slogan "Advancing new therapies that direct the body how to fight and beat cancer" encapsulates their mission to provide innovative solutions in cancer treatment. Tychon Biosciences is focused on commercializing a first-in-class bi-specific nanoring platform called BiND, which targets both an antigen receptor on a cancer cell and T-cell, enabling natural T-cell attacks on cancer cells without genetic engineering. This technology offers high-specificity cancer killing with increased safety and decreased cost compared to existing therapies. The company operates in the Biopharma, Biotechnology, and Life Sciences industries, reflecting its commitment to cutting-edge medical advancements. Currently, specific details regarding headquarters and last investment are not available. Tychon Biosciences presents an intriguing opportunity for investors seeking to support groundbreaking technologies in the fight against cancer.